Welcome to the latest edition of our weekly EuroBiotech Report. With AstraZeneca now back in play--if it chooses--talk of M&A involving European drugmakers has ratcheted up once again after a brief, post-Shire lull. But Novo Nordisk has no plans to get involved as a buyer or seller, with the Danish company's CEO confident the company has enough in-house insulin innovation to continue growing quickly without a big buyout. Smaller deals are possible though. Sweden's Cortendo--which has a diabetes-focused subsidiary--got a new CEO this week, with former Shire executive Matthew Pauls starting at the company. Pauls has a full agenda. Cortendo is planning to go public in the fourth quarter and is trying to make up time in a Phase III trial. Ablynx is preparing for a Phase III trial of its lead candidate while trimming its preclinical pipeline. TiGenix is further along with its late-stage study, the completion date for which has ebbed and flowed. Having put the date on which data is expected back from the second half of 2014 to the third quarter of 2015, the Belgian biotech has now inched its timeline forward. Innate Pharma reaffirmed its plans to advance its cutaneous T-cell lymphoma candidate into Phase I next year after the European Commission awarded the antibody orphan drug status. And more. Read the full EuroBiotech Report >>
Our annual top women in biotech report spotlights women in the life sciences industry, academia and regulatory roles who are outstanding members of the field. Our nomination form for this year's report is now open and I'd like to encourage you to submit your nominations below or click here. The deadline for nominations is September 1.
The big question right now in biopharma is where real innovation is coming from, and nothing says innovation quite like a blockbuster sales estimate on a high-profile, late-stage program with some near-term potential for approval.
In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd.
Like we always do about this time of year, FierceBiotech is kicking off its search for the next class of Fierce 15 companies, and we want to hear from you. It's easy: Just fill out the form embedded below or find it here.
We're looking for the brightest and bravest among private biotechs, and reader nominations complement our research, interviews and debates in assembling the list each year. Take this opportunity to chime in and tell us what makes your nominee worthy of the Fierce 15.
POPULAR COMMENT THREADS
Amgen has taken another big step in its head-to-head race with Sanofi and Regeneron, filing its application for the prospective cholesterol blockbuster evolocumab and backing it up with more positive data from the latest in a long string of major clinical studies.
Disappointing sales of ThromboGenics' only marketed product, Jetrea, have taken their toll on the company's profits this year. To get back in the black, the Belgian company now says it's spinning out its cancer R&D activities to focus on the struggling eye drug.
Some well-known biopharma execs on the West Coast, including Impax Labs founder and former CEO Larry Hsu, have teamed up on a low budget, late-stage program for an oral anticoagulant.
From Our Sister Sites
Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs?
The latest in a series of guidances explaining and implementing last year's Unique Device Identification final rule is "little more than a regurgitation of information contained in the rule itself, the preamble to the rule, the UDI website, and the Global Unique Device Identification (GUDID) guidance document," wrote medical device law attorney Jennifer Newberger.